Rationale and design of a randomized clinical trial of β-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome Academic Article uri icon

Overview

MeSH Major

  • Adrenergic beta-Antagonists
  • Angiotensin II Type 1 Receptor Blockers
  • Atenolol
  • Losartan
  • Marfan Syndrome

abstract

  • This randomized trial should make a substantial contribution to the management of individuals with MFS and expand our understanding of the mechanisms responsible for the aortic manifestations of this disorder.

publication date

  • October 2007

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3042860

Digital Object Identifier (DOI)

  • 10.1016/j.ahj.2007.06.024

PubMed ID

  • 17892982

Additional Document Info

start page

  • 624

end page

  • 31

volume

  • 154

number

  • 4